Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 62.22 Thousand USD | -636.32% |
| 2022 | 127.32 Thousand USD | 23.13% |
| 2021 | 103.41 Thousand USD | 107.28% |
| 2020 | 49.88 Thousand USD | 103.79% |
| 2019 | 24.48 Thousand USD | 1744.76% |
| 2018 | 1327.00 USD | -34.57% |
| 2017 | 2028.00 USD | -40.41% |
| 2016 | 3403.00 USD | 365.44% |
| 2015 | -1282.00 USD | -100.53% |
| 2014 | 242.09 Thousand USD | -19.24% |
| 2013 | 299.76 Thousand USD | -85.8% |
| 2012 | 2.11 Million USD | 29.7% |
| 2011 | 1.62 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 14.32 Million USD | 8761.32% |
| 2024 Q2 | -167.81 Thousand USD | -99.91% |
| 2023 Q1 | 14.65 Thousand USD | 139.16% |
| 2023 FY | -682.87 Thousand USD | -636.32% |
| 2023 Q4 | -165.37 Thousand USD | -100.89% |
| 2023 Q3 | 18.67 Million USD | 119561.73% |
| 2023 Q2 | 15.6 Thousand USD | 6.5% |
| 2022 Q1 | 68.96 Thousand USD | 136.05% |
| 2022 Q4 | -37.42 Thousand USD | -156.92% |
| 2022 Q2 | 30.04 Thousand USD | -56.44% |
| 2022 Q3 | 65.75 Thousand USD | 118.88% |
| 2022 FY | 127.32 Thousand USD | 23.13% |
| 2021 Q4 | 29.21 Thousand USD | -34.88% |
| 2021 Q1 | 9980.00 USD | -27.05% |
| 2021 Q2 | 19.35 Thousand USD | 93.97% |
| 2021 Q3 | 44.86 Thousand USD | 131.74% |
| 2021 FY | 103.41 Thousand USD | 107.28% |
| 2020 FY | 49.88 Thousand USD | 103.79% |
| 2020 Q1 | 16.02 Thousand USD | 275.62% |
| 2020 Q2 | 11.55 Thousand USD | -27.87% |
| 2020 Q3 | 8627.00 USD | -25.36% |
| 2020 Q4 | 13.68 Thousand USD | 58.57% |
| 2019 Q3 | 10 Thousand USD | 26.66% |
| 2019 Q2 | 7895.00 USD | 240.6% |
| 2019 Q1 | 2318.00 USD | 182.08% |
| 2019 Q4 | 4266.00 USD | -57.34% |
| 2019 FY | 24.48 Thousand USD | 1744.76% |
| 2018 Q3 | 2741.00 USD | 199.56% |
| 2018 FY | 1327.00 USD | -34.57% |
| 2018 Q1 | 495.00 USD | -31.35% |
| 2018 Q2 | 915.00 USD | 84.85% |
| 2018 Q4 | -2824.00 USD | -203.03% |
| 2017 FY | 2028.00 USD | -40.41% |
| 2017 Q4 | 721.00 USD | 64.24% |
| 2017 Q3 | 439.00 USD | -15.25% |
| 2017 Q2 | 518.00 USD | 48.0% |
| 2017 Q1 | 350.00 USD | -77.66% |
| 2016 Q4 | 1567.00 USD | 69.04% |
| 2016 Q1 | 390.00 USD | 122.11% |
| 2016 Q3 | 927.00 USD | 78.27% |
| 2016 FY | 3403.00 USD | 365.44% |
| 2016 Q2 | 520.00 USD | 33.33% |
| 2015 Q3 | 159.00 USD | -50.77% |
| 2015 Q4 | -1764.00 USD | -1209.43% |
| 2015 FY | -1282.00 USD | -100.53% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q2 | 323.00 USD | 0.0% |
| 2014 FY | 242.09 Thousand USD | -19.24% |
| 2014 Q1 | 73.49 Thousand USD | 15.04% |
| 2014 Q4 | 168.59 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2013 Q2 | 87.02 Thousand USD | -16.61% |
| 2013 FY | 299.76 Thousand USD | -85.8% |
| 2013 Q4 | 63.88 Thousand USD | 20.73% |
| 2013 Q1 | 104.35 Thousand USD | -78.24% |
| 2013 Q3 | 52.91 Thousand USD | -39.19% |
| 2012 Q1 | 593.91 Thousand USD | 8.52% |
| 2012 Q4 | 479.53 Thousand USD | 6.07% |
| 2012 Q3 | 452.08 Thousand USD | -22.85% |
| 2012 FY | 2.11 Million USD | 29.7% |
| 2012 Q2 | 585.97 Thousand USD | -1.34% |
| 2011 Q3 | 546.61 Thousand USD | 2.42% |
| 2011 Q4 | 547.28 Thousand USD | 0.12% |
| 2011 FY | 1.62 Million USD | 0.0% |
| 2011 Q1 | 416.00 USD | 0.0% |
| 2011 Q2 | 533.67 Thousand USD | 128186.54% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2651.292% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.468% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 119.476% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.948% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.241% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 228.942% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 150.081% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.585% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -1905.996% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.365% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 5.328% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 282.214% |
| Mesoblast Limited | -35.16 Million USD | 100.177% |
| Marizyme, Inc. | 457.7 Thousand USD | 86.405% |
| Genus plc | 178.7 Million USD | 99.965% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.972% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 84.829% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 665.691% |
| ContraFect Corporation | -154 Thousand USD | 140.406% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 224.452% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 18.935% |
| IMV Inc. | -962.29 Thousand USD | 106.466% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 116.058% |
| MultiCell Technologies, Inc. | 49.32 USD | -126067.883% |
| ONE Bio Corp. | 20.12 Million USD | 99.691% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.845% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -27.252% |
| Q BioMed Inc. | -8988.00 USD | 792.323% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.78% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 503.436% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.86% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 105.451% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 11.106% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1356.583% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 55.711% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 163.812% |
| GB Sciences, Inc. | -624.00 USD | 10072.115% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 172.332% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 30016.346% |
| Enzolytics Inc. | 30.7 Thousand USD | -102.638% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 87.102% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 112.094% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 89.921% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.985% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 802.642% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 174.212% |
| Kadimastem Ltd | -630.13 Thousand USD | 109.875% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 93.702% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.353% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.597% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 625.779% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 64.756% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 64.756% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 95.415% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 314.572% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 86.173% |
| SYBLEU INC | 11.69 Thousand USD | -432.028% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.65% |
| Bioxytran, Inc. | -8285.00 USD | 851.068% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 116.683% |
| Neutra Corp. | 14.33 Thousand USD | -334.084% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 175.885% |
| PureTech Health plc | -1.6 Million USD | 103.882% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 106.215% |
| IXICO plc | 3.27 Million USD | 98.097% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 108.966% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 103.474% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -245.7% |